Given a trend of increased ACAT-1 expression, concomitantly with higher CE content after CDDP treatment, this enzyme plays an important role in triggering metabolic changes in BC cells, contributing to the increased proliferation rate of MDA-MB-231 and different responses to anti-cancer therapy. Here, ACAT1 is linked to breast cancer.